Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 389 participants.

Also called NCT01193101

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 389 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01193101
Other papers using this trial's data
  • Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study Hypertension (Dallas, Tex. : 1979), 2014-04 DOI, PubMed 24446062

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Japan, South Korea, Taiwan, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01193101. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-04 (actual). Results posted on 2015-08-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
Condition
Hypertension
Intervention (Drug)
LCZ696
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01193101
Content hash
8bf0bd237d5afdf5354b3d64f9301e724cbcd932ec969a51625cf6779fa3aaf2